Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching.
about
Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Inhibition of melanogenesis by the pyridinyl imidazole class of compounds: possible involvement of the Wnt/β-catenin signaling pathwaySystems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.Pentoxifylline Inhibits WNT Signalling in β-Cateninhigh Patient-Derived Melanoma Cell PopulationsWnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells.Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanomaWNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner.Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.Phenotype switching in melanoma: implications for progression and therapy.MITF in melanoma: mechanisms behind its expression and activity.Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanomaMITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.Gene expression profiling of the synergy of 5-aza-2'-deoxycytidine and paclitaxel against renal cell carcinoma.Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell linesWnt interaction and extracellular release of prominin-1/CD133 in human malignant melanoma cells.The role of Wnt/β-catenin signaling pathway in melanoma epithelial-to-mesenchymal-like switching: evidences from patients-derived cell lines.Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.The small GTPase ARF6 stimulates β-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis.The gluttonous side of malignant melanoma: basic and clinical implications of macroautophagy.The three M's: melanoma, microphthalmia-associated transcription factor and microRNA.Melanoma metastasis: new concepts and evolving paradigms.Melanoma cells revive an embryonic transcriptional network to dictate phenotypic heterogeneity.Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy.Novel regulation of melanogenesis by adiponectin via the AMPK/CRTC pathway.A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.The WNT-less wonder: WNT-independent β-catenin signaling.Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.Expression and proliferation-promoting role of lymphoid enhancer-binding factor 1 in human clear cell renal carcinoma.Protein tyrosine phosphatase ζ enhances proliferation by increasing β-catenin nuclear expression in VHL-inactive human renal cell carcinoma cells.Beta-catenin inhibits melanocyte migration but induces melanoma metastasisPHF19 and Akt control the switch between proliferative and invasive states in melanoma.MiR-557 works as a tumor suppressor in human lung cancers by negatively regulating LEF1 expression.Systematic classification of melanoma cells by phenotype-specific gene expression mapping.MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression.A geometric approach to characterize the functional identity of single cells.Lithium induces mesenchymal-epithelial differentiation during human kidney development by activation of the Wnt signalling system.Epstein-Barr virus stably confers an invasive phenotype to epithelial cells through reprogramming of the WNT pathway.Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1.Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases.
P2860
Q26782222-E985C97C-222F-4D2B-B313-7F06B5AFD2AAQ28481465-53F481B6-978E-483D-AC9C-2AA6C7A7C454Q28548486-A397EAC2-162F-4358-AD58-9CFB712EABF6Q28552213-D39C630D-3343-4280-8ED2-03934B1EB25AQ30620714-BC382B52-7579-4F9B-887C-4FCDD0A3FBB9Q33762715-EF7398AD-4008-4CCD-8AE5-6596CE391FB0Q33785885-29FADA9D-5780-4AA2-8509-4D02544D82ECQ34802543-00EA4818-217F-41D9-98F1-EC0604A356E9Q35081779-8007B54C-9516-4493-B8B4-5CEE2906AD22Q35187734-CFE1F5E0-9EC5-4A95-900B-DAE21AF77BC8Q35229597-692C75F6-BC43-4469-9C3E-F56184EE4164Q36320144-15D64BCF-8E86-469E-88C4-80FEEA3422F0Q36348109-C710249F-6411-4C6C-9431-B0FEFC301970Q36381496-2A86C228-F38A-49E1-9137-149D377664EAQ36673662-7D256DDA-16B2-4121-AE8C-F6925C53A7C1Q37536551-CD59EE45-30AF-4A90-839E-5F5E9803414AQ37570262-C92A55F8-E044-4BBD-9833-42E035059241Q37651978-978518EA-240E-4EF8-9226-3DA18F0B8DF5Q37945272-D90D50DE-ECCB-4D09-81A4-E22D0F7CEA80Q37946457-BB4C0314-B465-4917-83A6-870045445221Q38111220-D7952B3F-9E11-4088-81D3-95BE6E033D76Q38299938-1EE342B4-90BD-4DC8-B6CF-E396C0773EFAQ38394400-7332CB34-5959-4D37-9494-2FD4D52850B4Q38403168-C058ECF3-1FCE-4E58-8F81-4E0D34B1C95CQ38757495-6E0D03B8-3C4C-4683-B4EE-392A54280228Q38842819-75B98D22-69DD-4967-A511-9AB214F90109Q38867422-1E61C1A0-5262-471E-9D7D-EC9E7C383750Q38943432-EF402B28-4E45-4F25-8CC7-04EDA0892B1AQ38988373-87798293-000D-40BA-B37D-C0D7D1D04A09Q39165981-C9728CD8-4030-4294-BF5F-2A6B9E981DE7Q39337123-6A5F1CFC-F1B2-45AB-BA7D-F1ADAC8BC7B0Q39367412-9A5B5A0A-5B67-49E5-9D76-D014BC5B757FQ40162309-E28346BD-CB05-4941-BCEF-BE87729D25B0Q42818733-49DC08E2-6045-4CFE-A33F-491B61480043Q50014278-F6A727B5-D4A7-49DA-986B-392A73331457Q52582070-3DC5FC0C-0BFA-41DD-B097-C8452640F3DEQ52659230-8D929C55-AC73-4305-8673-C58A876785A1Q54256444-0E47B6A5-6CA9-4A87-99B7-86EBAA54DB41Q54334679-C48206A6-DC44-4BA9-9943-905091D9D4C6Q54982136-FC3A7A13-DC5E-4CF4-BE6D-260631BCC8FF
P2860
Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching.
@en
Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching.
@nl
type
label
Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching.
@en
Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching.
@nl
prefLabel
Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching.
@en
Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching.
@nl
P2093
P2860
P1476
Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching.
@en
P2093
Ashani Weeraratna
Daniel S Widmer
Keith S Hoek
Laurence Denat
Lionel Larue
Lydia Kriegl
Marie C Zipser
Ossia M Eichhoff
Reinhard Dummer
P2860
P304
P356
10.1111/J.1755-148X.2011.00871.X
P577
2011-06-09T00:00:00Z